Navigation Links
Rare Cases of Liver Damage Tied to Weight-Loss Drug
Date:5/26/2010

Orlistat is available by prescription under trade name Xenical and over-the-counter as Alli

WEDNESDAY, May 26 (HealthDay News) -- Responding to reports of rare but sometimes severe cases of liver damage, U.S. health officials on Wednesday announced revised labels for a widely used weight-loss drug.

The drug, orlistat, is available by prescription under the trade name Xenical and over-the-counter as Alli.

Thirteen cases of severe liver injury have been associated with taking orlistat, 12 of them overseas and one of them, from Alli, in the United States, according to a statement from the U.S. Food and Drug Administration.

Still, given that some 40 million people worldwide are taking the drug, according to FDA estimates, consumers needn't be too worried about the risk, said Dr. Eugene Schiff, director of the Center for Liver Diseases at the University of Miami Miller School of Medicine.

"The issue here is that they are identifying cases, not many, but some cases of severe liver injury," he said.

"We are telling consumers and health-care providers to be vigilant should [patients] develop symptoms suggestive of liver impairment," said FDA spokeswoman Elaine Gansz Bobo. "We are not advising routine monitoring of liver enzymes as that will not help predict who may develop hepatic impairment on the drug. We were unable to identify any particular group that may be at increased risk."

At this time, FDA officials are only stating that there is an association between the rare side effect and the drug. It's not known if the drug actually causes the problem. It appears that some people simply metabolize the drug differently, putting them at higher risk. It's also possible that a contaminant was introduced, Schiff said.

The FDA first approved orlistat as a prescription medicine in 1999. In 2007, it became the first nonprescription drug approved to treat obesity in American adults.

The FDA started a review of orlistat for possible incidents of liver damage in August 2009. That announcement followed reports of 32 cases of serious liver injury, including six cases of liver failure between 1999 and October 2008. Two of those cases occurred in the United States.

Most of those patients reported having jaundice, weakness and abdominal pain -- all signs of liver damage. For 27 patients, the symptoms were severe enough to require hospitalization.

Wednesday's announcement referenced far fewer cases.

The 13 cases cited by the FDA Wednesday "were cases that, on review and categorization by the agency, received severity scores of 4 or 5 using the Drug Induced Liver Injury Network scoring system," Gansz Bobo explained. "Basically, a '5' means resulting in death or liver transplantation, and a '4' means it was severe and required hospitalization."

She said that the agency then took these "cases of significance" and determined that they were either "likely" or "possibly" related to the use of orlistat.

That explanation made sense to Schiff. "When the [original] cases were analyzed, they probably found good explanations for most of them," he said. "For the remaining 13, the only explanation [seemed to be] that they took orlistat."

Dr. Timothy Pfanner, an assistant professor of internal medicine at Texas A&M Health Science Center College of Medicine and a gastroenterologist with Scott & White in Temple, Texas, said: "The bottom line is it's still a rare event when you think about 40 million people taking the drug and we're just now picking up these effects and it's been around a long time."

"The problem," he added, "is patients can benefit from the medication on the one hand but, on the other hand, you need to be aware that all medications, including herbal products, that you put in your body have side effects."

Patients should see their doctor if they develop dark urine, itching or yellow skin or eyes, Pfanner said.

According to the U.S. National Center for Health Statistics, 30 percent of American adults aged 20 and older -- more than 60 million people -- are obese. Another 36 percent are considered overweight.

Orlistat is also approved in some 100 countries, with an over-the-counter form available in the European Union.

More information

The U.S. Food and Drug Administration has more about the safety of orlistat.



SOURCES: May 26, 2010, news release, U.S. Food and Drug Administration; Elaine Gansz Bobo, spokeswoman, U.S. Food and Drug Administration; Eugene Schiff, M.D., professor, medicine, and director, Center for Liver Diseases, University of Miami Miller School of Medicine; Timothy Pfanner, M.D., assistant professor of internal medicine, Texas A&M Health Science Center College of Medicine, and gastroenterologist, Scott & White, Temple, Texas


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Natural Delivery OK in Cases of Intrauterine Growth Restriction
2. Curing more cervical cancer cases may be in the math
3. U.S. Swine Flu Cases Chart Sharp Decline
4. Diabetes Cases Expected to Double in 25 Years
5. Memorial Blood Centers Showcases New Vehicle
6. U.S. Cancer Cases, Deaths Continue to Drop
7. Los Angeles Healthcare Fraud Defense Lawyers Announce Recent Results in California Medi-Cal and Medi-Care Criminal Law Cases
8. Alex & Gaxiola Legal Team Files Bold Motions to Disqualify Maricopa County Attorney's Office in Criminal Cases Pending in Superior Court
9. In San Diego, Hispanics Now Dominate HIV/TB Cases
10. Prednisolone not benficial in most cases of community-acquired pneumonia
11. Avoiding Dairy Due to Lactose Intolerance is Unnecessary in Most Cases and May Pose Diet and Health Risks, Concludes National Institutes of Health Consensus Development Conference Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... , ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch ... Glitch users can easily reveal any logo with a glitch reveal in just a few ... over the style and animation of each preset. Use these presets to add a uniquely ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its ... products. Ken was impressed with the safety and reliability of the Stannah Stairlift ... his show. This endorsement by Ken Matthews can be heard on News Radio ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is ... in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly ... one roof. Smiles by Seese serves patients of all ages with excellence in general, ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, http://www.fdanews.com/deviceapproval ... asking before selecting an FDA approval pathway? , How should they evaluate ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... by fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced ... Success program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... analytics for the US, Canada , Japan ... Latin America , and Rest of World. Annual estimates ... six-year historic analysis is provided for these markets. Market data and analytics ...
(Date:2/17/2017)... , Feb. 17, 2017 Arvinas LLC, a ... based on protein degradation, today announced the presentation of ... PROTAC during a poster session at the American Society ... in Orlando, FL. ... our platform and the potential of PROTACs to drive ...
(Date:2/17/2017)...   Risperdal lawsuits involving gynecomastia (male breast growth) ... of the atypical antipsychotic medication continue to move forward ... Common Pleas, where the state,s Risperdal docket has been ... notice posted on the Court,s website , the ... 9, 2017 at 11:00 a.m. (In Re: Risperdal Litigation, ...
Breaking Medicine Technology: